Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21247645 | 0.92 | CA9 (0.44) | CA9TDP2LMNAMAPTRAB9A | |
| SCHEMBL30839539 | 0.92 | CA9 (0.44) | CA9TDP2LMNAMAPTRAB9A | |
| SCHEMBL30468395 | 0.81 | CA9 (0.46) | CA9TDP2LMNAMAPTRAB9A | |
| SCHEMBL2061785 | 0.81 | CA9 (0.46) | CA9TDP2LMNAMAPTRAB9A | |
| SCHEMBL2616913 | 0.80 | TDP2 (0.54) | CA9TDP2LMNAMAPTRAB9A | |
| SCHEMBL2061036 | 0.80 | CA9 (0.43) | CA9TDP2LMNAMAPTRAB9A | |
| SCHEMBL2062134 | 0.79 | CA9 (0.56) | CA9TDP2LMNAMAPTRAB9A | |
| SCHEMBL2061223 | 0.78 | CA9 (0.46) | CA9TDP2LMNAMAPTRAB9A | |
| SCHEMBL6583487 | 0.77 | CA9 (0.49) | CA9TDP2LMNAMAPTRAB9A | |
| SCHEMBL17244491 | 0.77 | METAP1 (0.44) | TDP2MAPTRAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | CA9 2906/4885TDP2 793/4885LMNA 4717/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | CA9 3103/4885TDP2 380/4885LMNA 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.